Serum
PREGNANCY RECOMMENDATION: Compatible
BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible
PREGNANCY SUMMARY
The American College of Obstetricians and Gynecologists recommends the use of immune globulin intramuscular (IGIM) for postexposure prophylaxis of hepatitis A and measles (rubeola) (1). No risk to the fetus from this therapy has been reported (2).
FETAL RISK SUMMARY
A solution of immunoglobulin, primarily immunoglobulin G, IGIM is prepared from pooled plasma that takes 2–5 days to obtain adequate serum levels (3). It is indicated for postexposure prophylaxis of hepatitis A and measles (rubeola) and in the prevention of serious infections in patients with immunoglobulin deficiencies. In cases of rubella exposure of the pregnant woman, IGIM administered as soon as possible after exposure may prevent or modify maternal infection, but there is no evidence that it will prevent fetal infection (4). However, its use in such cases may be of benefit in women who will not consider therapeutic abortion.
BREASTFEEDING SUMMARY
No reports describing the use of IGIM during human lactation have been located.
References
1.American College of Obstetricians and Gynecologists. Immunization during pregnancy. ACOG Committee Opinion. No. 282, January 2003. Obstet Gynecol 2003;101:207–12.
2.CDC. Guidelines for vaccinating pregnant women. Available at www.cdc.gov/vaccines/pubs/preg-guide.htm. Accessed May 16, 2010.
3.Product information. Gammar. Armour Pharmaceutical Co., 1993.
4.American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics, and Washington, DC: American College of Obstetricians and Gynecologists, 1992:129.